<\/p>\n
Oxyspas<\/strong> bevat oxybutynin chloride<\/strong> — a tertiary amine anticholinergic \/ antimuscarinic drug used to treat overactive bladder (OAB)<\/strong> with symptoms of urgency, frequency, and urge incontinence. Available in 2.5 mg and 5 mg tablets<\/strong>. Oxybutynin is the oldest and most-prescribed OAB drug worldwide. It blocks M3 muscarinic acetylcholine receptors on the bladder detrusor, reducing involuntary contractions during filling. Standard adult dose: 5 mg two-to-three times daily<\/strong> (10-15 mg total\/day); start at 2.5 mg twice daily in the elderly or anyone susceptible to anticholinergic side effects. Meest voorkomende bijwerkingen:<\/strong> dry mouth (50%+), constipation, blurred vision, drowsiness, dizziness, urinary retention. Use with caution in adults aged 65+<\/strong> — the 2023 American Geriatrics Society Beers Criteria classifies oxybutynin as “potentially inappropriate” in older adults due to anticholinergic-related fall, cognitive, and delirium risk. Mirabegron is the preferred first-line OAB drug in older patients.<\/strong><\/p>\n<\/div>\n \ud83d\udce6 Elke bestelling is gedekt door onze Reshipment Assurance Policy<\/strong><\/a> \u2014 als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.<\/p>\n <\/p>\n Elke batch wordt ingekocht bij een WHO-GMP gecertificeerde fabrikant<\/strong>. Bestellingen worden verzonden in eenvoudige, ongemarkeerde verpakkingen door onze logistieke partners en vallen onder onze Reshipment Assurance Policy<\/a>: als een pakket niet binnen 20 werkdagen arriveert, sturen wij kosteloos een nieuwe zending, zonder vragen te stellen.<\/p>\n Oxyspas is a brand of oxybutynin chloride<\/strong> immediate-release tablets, available in 2.5 mg and 5 mg strengths<\/strong>. Internationally branded as Ditropan (US, UK, EU, AU), Cystrin (UK), Lyrinel XL (extended-release), Oxytrol (transdermal patch), Gelnique (gel). Pack sizes available at MedsBase: 30, 60, 90 or 180 tablets per strength.<\/p>\n Oxybutynin is a competitive antagonist at M1, M2 and M3 muscarinic acetylcholine receptors<\/strong>. The clinically relevant action is blockade of M3 receptors on the bladder detrusor smooth muscle — this reduces parasympathetic-driven detrusor contractions during the filling phase, decreasing urgency and incontinence episodes and increasing functional bladder capacity.<\/p>\n The dry-mouth, constipation, blurred-vision, and CNS side effects are the consequences of the SAME mechanism acting at non-bladder muscarinic receptors throughout the body — salivary glands (M3), gut (M2\/M3), ciliary muscle of the eye (M3), and the central nervous system (M1\/M2). Newer “uroselective” antimuscarinics (solifenacin, darifenacin) have somewhat better selectivity for bladder M3, but the difference is modest. Mirabegron, a \u03b23 agonist with a completely different mechanism, avoids these side effects altogether.<\/p>\n Adults:<\/strong><\/p>\n Children >5 years for nocturnal enuresis:<\/strong> 2.5-5 mg at bedtime, paediatric supervision essential.<\/p>\n Renal\/hepatic impairment:<\/strong> reduce starting dose; titrate cautiously. Severe hepatic impairment is a relative contraindication.<\/p>\n Oxybutynin is the most strongly anticholinergic of the OAB drugs and crosses the blood-brain barrier readily. In adults aged 65+, the cumulative anticholinergic burden from oxybutynin (often combined with other anticholinergics in the medication list) is associated with measurable cognitive decline, increased fall risk, and emerging evidence of long-term dementia risk in observational studies.<\/p>\n Practical implications:<\/p>\n Do not take oxybutynin if you have:<\/strong><\/p>\n Wees voorzichtig bij:<\/strong> elderly age (see above), benign prostatic hyperplasia (urinary retention risk), reflux oesophagitis, autonomic neuropathy, hyperthyroidism, coronary artery disease, hypertension, arrhythmia, dementia or cognitive impairment.<\/p>\n Zwangerschap en borstvoeding:<\/strong> use only if benefit outweighs risk.<\/p>\nWaarom bestellen bij MedsBase<\/h3>\n
\n
What is Oxyspas?<\/h2>\n
How oxybutynin works<\/h2>\n
When oxybutynin is used<\/h2>\n
\n
Dosering & hoe in te nemen<\/h2>\n
\n
Bijwerkingen & veiligheid<\/h2>\n
\n
Anticholinergic burden & the elderly<\/h2>\n
\n
Contra-indicaties & waarschuwingen<\/h2>\n
\n
Geneesmiddelinteracties<\/h2>\n
\n
How oxybutynin compares<\/h2>\n